Search Results
Your search for ,aGe matches 8736 pages
Showing 2201 - 2250FDA Expands Eligibility for COVID-19 Vaccine Boosters
On November 19, the U.S. Food and Drug Administration (FDA) amended the emergency use authorizations (EUA) for both the Moderna and Pfizer-BioNTech COVID-19 vaccines authorizing use of a single booster dose for all individuals aged 18 years and older after completion of primary vaccination with any ...
Development of Phenotypic Spectrum Categorization for Li-Fraumeni Syndrome
In a study reported in JAMA Oncology, Kratz et al analyzed data from the International Agency for Research on Cancer (IARC) TP53 Database to define a phenotypic spectrum categorization for Li-Fraumeni syndrome. As stated by the investigators, “Li-Fraumeni syndrome is a cancer predisposition...
Immunotherapy Followed by Targeted Therapy Yields Greater Overall Survival in Patients With BRAF V600–Mutated Advanced Melanoma
Patients with BRAF V600–mutated advanced melanoma who received an immunotherapy regimen of nivolumab/ipilimumab followed by targeted therapy with dabrafenib/trametinib experienced greater overall survival (72%) compared with patients receiving the converse sequence (52%). According to the study...
Study Reveals Genomic Differences Between 14 Tumor Types in Younger vs Older Adults
The results of a study published by Lee et al in Cell Reports suggest that several genetic hallmarks may play key roles in identifying precise treatment options for young adult patients with cancer. The investigators, who systematically compared the genomes of 14 different types of cancers that...
French Study Finds COVID-19 Vaccine Effective in Patients With Lung Cancer
In a new study published by Gounant et al in the Journal of Thoracic Oncology, researchers from France showed that SARS–CoV-2 vaccines are safe and effective in patients with thoracic cancer, most of whom are immunized after two doses. A third shot given to 11% of patients with persistent low...
Treatment Adherence, Toxicity, and Outcomes With Adjuvant Fluoropyrimidine Plus Oxaliplatin in Early-Onset Colorectal Cancer
In an analysis of data from the International Duration Evaluation of Adjuvant Chemotherapy (IDEA) database reported in the Journal of Clinical Oncology, Fontana et al found a greater risk of relapse and cancer-specific mortality after adjuvant fluoropyrimidine/oxaliplatin chemotherapy in patients...
Incidence of Pancreatic Cancer in the United States by Age and Sex, 2000–2018
In a study reported in a research letter in JAMA, Gaddam et al found that the incidence of pancreatic cancer has increased in both men and women between 2000 and 2018, with a greater relative increase being observed in younger women. Pancreatic cancer incidence rates per 100,000 population...
U.S. Multisociety Task Force on Colorectal Cancer Releases Updated Screening Recommendations
The U.S. Multisociety Task Force on Colorectal Cancer—representing the American College of Gastroenterology, the American Gastroenterological Association, and the American Society for Gastrointestinal Endoscopy—has updated its colorectal cancer screening recommendations, which were last published...
Use of Genomic Classifier Score May Help to Personalize Therapy for Men With High-Risk Prostate Cancer
A 22-genomic classifier (the Decipher score) was able to predict the course of disease in men with high-risk prostate cancer, according to a patient-level meta-analysis of three randomized clinical trials presented at the 2021 American Society for Radiation Oncology (ASTRO) Annual Meeting.1 Use of...
Immunogenicity of SARS–CoV-2 Vaccines in Patients With Cancer
In a single-institution prospective cohort study (CANVAX Cohort Study) reported in the Journal of Clinical Oncology, Naranbhai and colleagues assessed the immunogenicity of SARS–CoV-2 vaccines in patients with cancer. They found that immunogenicity varied among vaccines and that both antibody...
Effect of National HPV Vaccination Program on the Incidence of Cervical Cancer and Intraepithelial Neoplasia in Young Women in England
As reported in The Lancet by Falcaro et al, a register-based observational study has shown that the England national human papillomavirus (HPV) vaccine program, initiated in 2008 using a bivalent vaccine (Cervarix; HPV16/18), has been successful in reducing the rates of cervical cancer and grade 3...
De-escalation of Radiation Therapy for HPV-Positive, Intermediate-Risk Oropharyngeal Cancer
De-escalated adjuvant radiotherapy appears to be safe in patients with surgically resectable, human papillomavirus (HPV)--positive oropharyngeal cancers, particularly in patients without extranodal extension or pN2 disease by American Joint Committee on Cancer (AJCC) 8th edition. These findings...
No Survival Benefit but Improved Secondary Endpoints With Radiotherapy Plus Androgen Suppression in Intermediate-Risk Prostate Cancer
Both dose-escalated radiation therapy and short-course androgen-deprivation therapy have been shown to improve outcomes in intermediate-risk prostate cancer, but it is not clear whether giving both modalities upfront to newly diagnosed patients is of benefit. The phase III RTOG 0815 study presented ...
Outcomes and Toxicity With Single-Agent Immune Checkpoint Inhibitor Treatment in Patients With Cancer Aged ≥ 80 Years
In a multicenter international retrospective cohort study reported in JAMA Oncology, Nebhan et al found that single-agent immune checkpoint inhibitor therapy in patients with cancer aged ≥ 80 years appeared to be effective and generally well tolerated. As stated by the investigators, “Geriatric...
Showcasing 50 Years of Advances in Cancer Research and Treatment
The AACR Cancer Progress Report 2021, published on October 13, celebrates the gains made in cancer research since President Richard Nixon signed the National Cancer Act into law on December 23, 1971, especially against such life-threatening cancers as metastatic melanoma and lung cancer.1 The...
David Morse Livingston, MD, Scientist and Esteemed Mentor, Dies at 80
David Morse Livingston, MD, formerly the Charles A. Dana Chair in Human Cancer Genetics at Dana-Farber and the Emil Frei III Distinguished Professor of Medicine at Harvard Medical School, died unexpectedly on October 17, 2021. He was Deputy Director of the Dana-Farber/Harvard Cancer Center (DF/HCC) ...
Medication Nonadherence Among Cancer Survivors: Are Indirect Health-Care Costs to Blame?
Approximately 1 in 10 long-term survivors of cancer fails to take medications as prescribed due to financial hardship, according to research presented at the 2021 ASCO Quality Care Symposium.1 However, indirect health-care costs—not drug copays—may be responsible, the study investigators ...
WHO Director-General Grants Posthumous Award to Henrietta Lacks
World Health Organization (WHO) Director-General Tedros Adhanom Ghebreyesus, MD, honored the late Henrietta Lacks with a WHO Director-General’s award, recognizing her world-changing legacy. Ms. Lacks, a Black American woman, died of cervical cancer 70 years ago, on October 4, 1951. While she...
The Worst Part of Having Cancer Was the Guilt
When I was diagnosed with small cell lung cancer in 1992, at age 38, I remember thinking, “I wish I had breast cancer.” Breast cancer elicits such sympathy from people. A diagnosis of small cell lung cancer mainly gets you stern looks of disapproval and disappointment. There is so much stigma...
Cancer Researcher and Drug Developer, Joseph R. Bertino, MD, Dies at 91
Over the arc of his notable career, Joseph R. Bertino, MD, garnered many honors for his scientific contributions leading to curative treatments for leukemia and lymphoma, such as ASCO’s David A. Karnofsky Award. Yet his legacy was perhaps most prominently punctuated by the multitude of patients...
AML Pioneer and ‘Gentle Soul,’ Elihu H. Estey, MD, Dies at 75
“A lot of times, younger bright physicians are afraid to say what they really think, out of fear of challenging the dogma. One of the things I do when mentoring is to ask why we are doing a particular therapy or intervention. I tell my mentees not to let the data interfere with your knowledge,”...
Early Experiences in the United States Helped Shape an International Oncology Career for Aleix Prat, MD, PhD
In this installment of the Living a Full Life series, guest editor Jame Abraham, MD, spoke with Aleix Prat, MD, PhD, Head of the Medical Oncology Department, Hospital Clinic of Barcelona. Dr. Prat, a breast cancer researcher, is currently working to identify strategies to tailor treatment for...
CDK4/6 Inhibitors Combined With Fulvestrant for Hormone Receptor–Positive, HER2-Negative Advanced Breast Cancer: FDA Analysis of Overall Survival
In an exploratory U.S. Food and Drug Administration (FDA) pooled analysis reported in The Lancet Oncology, Jennifer J. Gao, MD, and colleagues found that the addition of CDK4/6 inhibitor treatment to fulvestrant resulted in a consistent overall survival benefit vs placebo plus fulvestrant in...
IMpower010: Adjuvant Atezolizumab Improves Disease-Free Survival and NSCLC Relapse in Patients Whose Tumors Express PD-L1
Adjuvant immunotherapy with atezolizumab after standard chemotherapy improved disease-free survival and time to locoregional and distant relapse compared with best supportive care in prespecified subgroups of patients with stage II to IIIA non–small cell lung cancer (NSCLC), according to an...
Risk-Reducing Medications for Breast Cancer Are Becoming Safer and More Tolerable
Risk-reducing medications for breast cancer may be effective for many women, and recently reported and ongoing trials have led to improvements in their tolerability and safety, Seema A. Khan, MD, reported at the 2021 Annual Lynn Sage Breast Cancer Symposium (virtual).1 Dr. Khan is Professor of...
Optimizing Adjuvant Therapy for Women With Estrogen Receptor–Positive, Node-Positive Breast Cancer
“Nodal status remains the single most important prognostic marker in outcomes for women with estrogen receptor–positive, HER2-negative breast cancer. For that reason, it makes sense to think about optimizing adjuvant therapy, including endocrine treatments, chemotherapy, and targeted therapy,”...
Racial Disparities in Use of Prostate MRI After Detection of Elevated PSA Levels
In a study published by Abashidze et al in JAMA Network Open, the investigators found that Black men were at least 23.6% less likely than White men to undergo magnetic resonance imaging (MRI) following an elevated prostate-specific antigen (PSA) test result. They also found that Hispanic and Asian...
Study Finds Lack of Health Insurance May Hinder Recommended Cancer Screening in Unemployed Adults
In a recent study published by Stacey Fedewa, PhD, and colleagues in the journal Cancer, unemployed individuals were less likely to have health insurance and be up to date on getting recommended cancer screening tests. Analyses revealed that their lack of health insurance coverage accounted for...
COVID-19 Sequelae Prevalence, Risk Factors, and Outcomes in Patients With Cancer
In a retrospective European study reported in The Lancet Oncology, David J. Pinato, PhD, and colleagues found that among patients with cancer who recovered from COVID-19 infection, a substantial proportion have sequelae that can affect survival and oncologic outcomes. Among patients on systemic...
Effect of Geriatric Assessment and Management Recommendations on Adverse Events Related to Cancer Treatment
In a U.S. cluster-randomized trial (GAP70+) reported in The Lancet, Supriya G. Mohile, MD, and colleagues found that geriatric assessment and management recommendations reduced the incidence of grade ≥ 3 toxicity vs usual care among patients aged ≥ 70 years with incurable advanced cancers who were...
Ibrutinib Plus R-CHOP for Younger Patients With DLBCL
New evidence suggests that adding the Bruton's tyrosine kinase (BTK) inhibitor ibrutinib to a standard chemotherapy regimen may improve survival among younger people with a specific form of diffuse large B-cell lymphoma (DLBCL). The findings, published by Wyndham Wilson, MD, PhD, in Cancer Cell,...
Study Finds Patients Infected With COVID-19 Who Underwent Recent Cancer Treatment Are at Higher Risk of Adverse Outcomes
In a cohort study reported in JAMA Oncology, Mariana Chavez-MacGregor, MD, MSc, and colleagues found that patients with cancer infected with COVID-19 had poorer outcomes vs patients without cancer if they had received recent cancer treatment. Patients with cancer who had not received recent...
Evidence for Efficacy of Sunitinib in Malignant Pheochromocytoma and Paraganglioma
Results from the phase II FIRSTMAPPP study support the potential use of the tyrosine kinase inhibitor sunitinib in two rare neuroendocrine malignancies—pheochromocytoma and paraganglioma. Sunitinib significantly improved the primary endpoint of progression-free survival vs placebo, according to...
Risks and Benefits Associated With Gastrostomy Tubes for Patients With Cancer
In a study published by Gauvin et al in JNCCN–Journal of the National Comprehensive Cancer Network, researchers examined over 200 patients with gastrostomy tubes and highlighted the need for a multidisciplinary approach to palliative care decision-making for patients with cancer. A gastrostomy tube ...
Retrospective Study Examines Real-World Survival in U.S. Women Treated for Early-Stage Breast Cancer
In a retrospective cohort study reported in JCO Oncology Practice, Gidwani et al found that among U.S. patients treated for early-stage breast cancer, those who were considered to be unrepresented in clinical trials have significantly poorer survival than those categorized as well represented....
Study Finds Younger B-Cell Non-Hodgkin Lymphoma Survivors May Have a Higher Risk of Age-Related Diseases Than Older Survivors
Non-Hodgkin lymphoma is one of the most common cancers diagnosed in the United States, accounting for nearly 4% of all cancers. This year, about 81,600 individuals will be diagnosed with non-Hodgkin lymphoma, and nearly 21,000 will die from the cancer. A study by Ocier et al published in Cancer...
Study Finds Type I Interferon May Enhance the Antileukemia Effect of Allogeneic Transplantation
In a study published by Magenau et al in the journal Blood Advances, researchers found that patients with high-risk acute myeloid leukemia (AML) who received a form of type I interferon after allogeneic hematopoietic stem cell transplant experienced reduced rates of disease relapse. Additionally,...
Role of Age at Smoking Start and Cessation in Risk of Overall Cancer Mortality Among Current Smokers vs Never-Smokers
In a study reported in a research letter in JAMA Oncology, Thomson et al found that current smokers had a threefold greater risk of overall cancer mortality between the ages of 25 and 79 years vs never-smokers, with risk being modulated according to age at smoking initiation and age at cessation in ...
Do Solid Organ Transplant Recipients With a Previous Cancer Diagnosis Have High Cure Probabilities?
In a study reported in the Journal of Clinical Oncology, Engels et al found that patients with a previous cancer diagnosis who underwent solid organ transplantation had high cancer cure probabilities. Additionally, posttransplantation cancer-specific survival was associated with cancer cure...
Patient-Reported Outcomes in Gastrointestinal Cancers: Predicting Treatment Response and Survival Outcomes
According to data presented during the 2021 ASCO Quality Care Symposium,1 1-month changes in patient-reported outcomes may predict treatment response and survival outcomes in patients with advanced gastrointestinal cancers. The results of a prospective study of 159 patients with metastatic...
Effect of Social Determinants of Health on Receipt of Survivorship Care Plans
Survivorship care plans are an important tool to help cancer survivors transition from active treatment to follow-up care, but a study published by Timsina et al in Supportive Care in Cancer has found that a number of vulnerable groups have a lower likelihood of receiving such plans. Cancer...
Characteristics, Effects, and Outcomes of SARS–CoV-2 Infection in Pediatric Patients With Cancer
In an article published in the Journal of Clinical Oncology, Emily E. Johnston, MD, MS, and colleagues detailed characteristics, effects on cancer treatment, and outcomes of SARS–CoV-2 infection in pediatric patients with cancer based on data from The Pediatric Oncology COVID-19 Case Report...
Overall Survival With Laparoscopic vs Open Distal Gastrectomy for Locally Advanced Gastric Cancer
As reported in JAMA Surgery by Huang et al, the Chinese phase III CLASS-01 trial has shown no difference in 5-year overall survival in patients with locally advanced gastric cancer who underwent laparoscopic vs open distal gastrectomy. The previously reported primary analysis of the trial showed no ...
FDA Authorizes Pfizer-BioNTech COVID-19 Vaccine for Emergency Use in Children Aged 5 Through 11 Years
On October 29, the U.S. Food and Drug Administration (FDA) authorized the emergency use of the Pfizer-BioNTech COVID-19 vaccine for the prevention of COVID-19 to include children aged 5 through 11 years. The authorization was based on the FDA’s thorough and transparent evaluation of the data that...
Study Finds Incidence of Pancreatic Cancer May Be Rising in Younger Women
The incidence of pancreatic cancer—which historically has been higher in men than in women—has increased among both men and women during the past decade, with a significantly greater relative increase observed in women younger than age 55 years, and especially among those aged 15 to 34 years. These ...
Rates of Occult Gastric Carcinoma in Patients With Hereditary Lobular Breast Cancer Due to CDH1 Genetic Variants
In a single-institution prospective cohort study reported in JAMA Surgery, Gamble et al found that patients with hereditary lobular breast cancer due to CDH1 variants also had a high prevalence of occult signet ring cell gastric carcinoma. Study Details The study involved 283 patients from 151...
First-Round Results of Prostate Cancer Screening for Men With Pathogenic Variants in Mismatch Repair Genes
As reported in The Lancet Oncology by Bancroft et al, the first round of prostate cancer screening in the IMPACT study of men with pathogenic variants in mismatch repair genes showed an increased risk of prostate cancer in carriers of MSH2 and MSH6 variants compared with noncarrier controls. As...
Patients With Multiple Myeloma May Lack T-Cell Responses to COVID-19 Vaccination
Patients with multiple myeloma lacking an antibody response to COVID-19 vaccine may also fail to mount a T-cell response, according to research from the Icahn School of Medicine at Mount Sinai. Concerningly, this scenario was most common among patients actively treated with anti-CD38 and...
Study Finds Similar Survival Rates Among Patients With Metastatic Colorectal Cancer Younger and Older Than Age 50
Even though patients with metastatic colorectal cancer younger than age 50 tend to be more fit and receive more intensive treatment than older patients, survival for both groups is roughly the same, according to a study published by Lipsyc-Sharf et al in the Journal of the National Cancer...
Phase III Trial Evaluates Efficacy of Total Androgen Suppression Plus Dose-Escalated Radiotherapy for Patients With Intermediate-Risk Prostate Cancer
Both dose-escalated radiation therapy and short-course androgen-deprivation therapy (SADT) have been shown to improve outcomes in patients with intermediate-risk prostate cancer. Researchers then posed a new question—is giving both modalities upfront to newly diagnosed patients of benefit? Findings ...
